From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal zone lymphoma?

Sonali M. Smith, MD
Associate Professor of Medicine Director, Lymphoma Program, The University of Chicago Medicine

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the meeting via an audience response system, but we want to know what you would do.

CLINICAL DILEMMA

A 67-year-old turkey farmer reports difficulty swallowing. A biopsy of his tonsils shows diffuse infiltration by monomorphic B cells: CD20-positive, CD10-negative, and CD5-negative.

A staging evaluation showed diffuse adenopathy and he is diagnosed with stage 3 nodal marginal zone lymphoma. He was treated initially with doxycycline but had a minimal response. He then received rituximab monotherapy and had a complete remission. Approximately 30 months later, he relapsed and was again treated with rituximab. One year later, he had a second symptomatic relapse and required therapy.

Which one of the following agents is NOT approved for this disease?

  1. rituximab
  2. ibrutinib
  3. copanlisib
  4. bortezomib

Let us know how you would respond at ashclinicalnews@hematology.org!

Here’s how audience members responded:

  • rituximab
  • ibrutinib
  • copanlisib
  • bortezomib

Here’s how ASH Clinical News readers responded:

  • rituximab
  • ibrutinib
  • copanlisib
  • bortezomib

Disclaimer: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk.

SHARE